Integration of Artificial Intelligence, Blockchain, and Wearable Technology for Chronic Disease Management: A New Paradigm in Smart Healthcare

Chronic diseases are a growing concern worldwide,with nearly 25% of adults suffering from one or more chronic health conditions,thus placing a heavy burden on individuals,families,and healthcare systems.With the advent of the“Smart Healthcare”era,a series of cutting-edge technologies has brought new experiences to the management of chronic diseases.Among them,smart wearable technology not only helps people pursue a healthier lifestyle but also provides a continuous flow of healthcare data for disease diagnosis and treatment by actively recording physiological parameters and tracking the metabolic state.However,how to organize and analyze the data to achieve the ultimate goal of improving chronic disease management,in terms of quality of life,patient outcomes,and privacy protection,is an urgent issue that needs to be addressed.Artificial intelligence(AI)can provide intelligent suggestions by analyzing a patient’s physiological data from wearable devices for the diagnosis and treatment of diseases.In addition,blockchain can improve healthcare services by authorizing decentralized data sharing,protecting the privacy of users,providing data empowerment,and ensuring the reliability of data management.Integrating AI,blockchain,and wearable technology could optimize the existing chronic disease management models,with a shift from a hospital-centered model to a patient-centered one.In this paper,we conceptually demonstrate a patient-centric technical framework based on AI,blockchain,and wearable technology and further explore the application of these integrated technologies in chronic disease management.Finally,the shortcomings of this new paradigm and future research directions are also discussed.

HPLC-MS analysis of Schisandra lignans and their metabolites in Caco-2 cell monolayer and rat everted gut sac models and in rat plasma

The absorption profiles of Schisandra chinensis were evaluated using the human Caco-2 cell monolayer and rat everted gut sac models,as well as in rat plasma.By analyzing the chromatographic and MSn characteristics of individual peak acquired by HPLC-DAD-APCI-MS^(n) determination,thirteen lignans were identified as the major in vitro absorbable components of the Schisandra extract.Most of these compounds were also detected and identified in rat plasma after an oral administration of the Schisandra extract,except for angeloyl(tigloyl)gomisin H and angeloyl(tigloyl)gomisin Q,whose structures possess an ester group at the cyclooctadiene ring.In addition,four metabolites,corresponding to the hydroxylation and demethylation products of schisandrin and the hydrolysis derivative of angeloyl(tigloyl)gomisin Q,were tentatively identified.The results demonstrate that Schisandra lignans are the major absorbable components of this crude drug,and hydroxylation,demethylation and hydrolysis are important metabolic transformations of the absorbable lignans.